Do analysts rate NTRB or ASBP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer ASBP or IXHL?

Incannex Healthcare has a consensus target price of $18.00, indicating a potential upside of 380.00%. Given Incannex Healthcare's stronger consensus rating and higher probable upside, analysts plainly believe Incannex Healthcare is more favorable than Aspire Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Incannex Healthcare 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor ASBP or IXHL?

In the previous week, Incannex Healthcare had 1 more articles in the media than Aspire Biopharma. MarketBeat recorded 3 mentions for Incannex Healthcare and 2 mentions for Aspire Biopharma. Incannex Healthcare's average media sentiment score of 1.00 beat Aspire Biopharma's score of 0.00 indicating that Incannex Healthcare is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aspire Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Incannex Healthcare 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer RFAI or ASBP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RF Acquisition Corp II 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, RFAI or ASBP?

RF Acquisition Corp II has higher earnings, but lower revenue than Aspire Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RF Acquisition Corp II N/A N/A N/A N/A N/A Aspire Biopharma $10K 1,157.80 -$24.48M -$69.62 N/A

Is RFAI or ASBP more profitable?

RF Acquisition Corp II has a net margin of 0.00% compared to Aspire Biopharma's net margin of -11,362.21%. Company Net Margins Return on Equity Return on Assets RF Acquisition Corp II N/A N/A N/A Aspire Biopharma -11,362.21% N/A -177.59%

Does the media refer more to RFAI or ASBP?

In the previous week, RF Acquisition Corp II had 11 more articles in the media than Aspire Biopharma. MarketBeat recorded 13 mentions for RF Acquisition Corp II and 2 mentions for Aspire Biopharma. RF Acquisition Corp II's average media sentiment score of 0.07 beat Aspire Biopharma's score of 0.00 indicating that RF Acquisition Corp II is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RF Acquisition Corp II 0 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aspire Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ADXS or ASBP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ADXS or ASBP more profitable?

Ayala Pharmaceuticals has a net margin of 0.00% compared to Aspire Biopharma's net margin of -11,362.21%. Company Net Margins Return on Equity Return on Assets Ayala Pharmaceuticals N/A N/A N/A Aspire Biopharma -11,362.21% N/A -177.59%

Do analysts recommend GRCE or ASBP?

Grace Therapeutics presently has a consensus target price of $6.00, indicating a potential upside of 172.73%. Given Grace Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Grace Therapeutics is more favorable than Aspire Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grace Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Aspire Biopharma (ASBP) Competitors

$8.27 +0.46 (+5.89%)

Closing price 08/25/2026 04:00 PM Eastern

Extended Trading

$8.38 +0.11 (+1.37%)

As of 08/25/2026 05:19 PM Eastern

Compare

ASBP vs. NTRB, IXHL, RFAI, ADXS, and GRCE

Should you buy Aspire Biopharma stock or one of its competitors? Aspire Biopharma's main competitors and comparable companies include Nutriband (NTRB), Incannex Healthcare (IXHL), RF Acquisition Corp II (RFAI), Ayala Pharmaceuticals (ADXS), and Grace Therapeutics (GRCE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Aspire Biopharma compare to Nutriband?

Nutriband (NASDAQ:NTRB) and Aspire Biopharma (NASDAQ:ASBP) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

In the previous week, Aspire Biopharma had 1 more articles in the media than Nutriband. MarketBeat recorded 2 mentions for Aspire Biopharma and 1 mentions for Nutriband. Nutriband's average media sentiment score of 0.00 equaled Aspire Biopharma'saverage media sentiment score.

Company	Overall Sentiment
Nutriband	Neutral
Aspire Biopharma	Neutral

Nutriband has a beta of 1.98, indicating that its stock price is 98% more volatile than the broader market. Comparatively, Aspire Biopharma has a beta of 0.11, indicating that its stock price is 89% less volatile than the broader market.

19.7% of Nutriband shares are held by institutional investors. Comparatively, 19.2% of Aspire Biopharma shares are held by institutional investors. 52.2% of Nutriband shares are held by company insiders. Comparatively, 5.8% of Aspire Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Nutriband has a net margin of -448.25% compared to Aspire Biopharma's net margin of -11,362.21%. Aspire Biopharma's return on equity of 0.00% beat Nutriband's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nutriband	-448.25%	-112.64%	-97.86%
Aspire Biopharma	-11,362.21%	N/A	-177.59%

Nutriband has higher revenue and earnings than Aspire Biopharma. Nutriband is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutriband	$2.04M	28.79	-$8.23M	-$2.58	N/A
Aspire Biopharma	$10K	1,157.80	-$24.48M	-$69.62	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Nutriband beats Aspire Biopharma on 9 of the 13 factors compared between the two stocks.

How does Aspire Biopharma compare to Incannex Healthcare?

Aspire Biopharma (NASDAQ:ASBP) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.

Aspire Biopharma has a beta of 0.11, suggesting that its share price is 89% less volatile than the broader market. Comparatively, Incannex Healthcare has a beta of 6.98, suggesting that its share price is 598% more volatile than the broader market.

In the previous week, Incannex Healthcare had 1 more articles in the media than Aspire Biopharma. MarketBeat recorded 3 mentions for Incannex Healthcare and 2 mentions for Aspire Biopharma. Incannex Healthcare's average media sentiment score of 1.00 beat Aspire Biopharma's score of 0.00 indicating that Incannex Healthcare is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aspire Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Incannex Healthcare	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Incannex Healthcare has a consensus target price of $18.00, indicating a potential upside of 380.00%. Given Incannex Healthcare's stronger consensus rating and higher probable upside, analysts plainly believe Incannex Healthcare is more favorable than Aspire Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Incannex Healthcare has a net margin of 0.00% compared to Aspire Biopharma's net margin of -11,362.21%. Aspire Biopharma's return on equity of 0.00% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aspire Biopharma	-11,362.21%	N/A	-177.59%
Incannex Healthcare	N/A	-81.01%	-76.11%

19.2% of Aspire Biopharma shares are held by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are held by institutional investors. 5.8% of Aspire Biopharma shares are held by insiders. Comparatively, 1.3% of Incannex Healthcare shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Aspire Biopharma has higher earnings, but lower revenue than Incannex Healthcare. Incannex Healthcare is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aspire Biopharma	$10K	1,157.80	-$24.48M	-$69.62	N/A
Incannex Healthcare	$90K	498.75	-$46.88M	-$1.55	N/A

Summary

Incannex Healthcare beats Aspire Biopharma on 10 of the 16 factors compared between the two stocks.

How does Aspire Biopharma compare to RF Acquisition Corp II?

RF Acquisition Corp II (NASDAQ:RFAI) and Aspire Biopharma (NASDAQ:ASBP) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

RF Acquisition Corp II has a net margin of 0.00% compared to Aspire Biopharma's net margin of -11,362.21%.

Company	Net Margins	Return on Equity	Return on Assets
RF Acquisition Corp II	N/A	N/A	N/A
Aspire Biopharma	-11,362.21%	N/A	-177.59%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RF Acquisition Corp II	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

RF Acquisition Corp II has higher earnings, but lower revenue than Aspire Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A
Aspire Biopharma	$10K	1,157.80	-$24.48M	-$69.62	N/A

19.2% of Aspire Biopharma shares are held by institutional investors. 39.1% of RF Acquisition Corp II shares are held by insiders. Comparatively, 5.8% of Aspire Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, RF Acquisition Corp II had 11 more articles in the media than Aspire Biopharma. MarketBeat recorded 13 mentions for RF Acquisition Corp II and 2 mentions for Aspire Biopharma. RF Acquisition Corp II's average media sentiment score of 0.07 beat Aspire Biopharma's score of 0.00 indicating that RF Acquisition Corp II is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RF Acquisition Corp II	0 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aspire Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

RF Acquisition Corp II beats Aspire Biopharma on 5 of the 7 factors compared between the two stocks.

How does Aspire Biopharma compare to Ayala Pharmaceuticals?

Ayala Pharmaceuticals (NASDAQ:ADXS) and Aspire Biopharma (NASDAQ:ASBP) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

Ayala Pharmaceuticals has a net margin of 0.00% compared to Aspire Biopharma's net margin of -11,362.21%.

Company	Net Margins	Return on Equity	Return on Assets
Ayala Pharmaceuticals	N/A	N/A	N/A
Aspire Biopharma	-11,362.21%	N/A	-177.59%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Ayala Pharmaceuticals has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market. Comparatively, Aspire Biopharma has a beta of 0.11, suggesting that its share price is 89% less volatile than the broader market.

In the previous week, Aspire Biopharma had 2 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 2 mentions for Aspire Biopharma and 0 mentions for Ayala Pharmaceuticals. Ayala Pharmaceuticals' average media sentiment score of 0.00 equaled Aspire Biopharma'saverage media sentiment score.

Company	Overall Sentiment
Ayala Pharmaceuticals	Neutral
Aspire Biopharma	Neutral

7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. Comparatively, 19.2% of Aspire Biopharma shares are owned by institutional investors. 0.6% of Ayala Pharmaceuticals shares are owned by insiders. Comparatively, 5.8% of Aspire Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Aspire Biopharma has lower revenue, but higher earnings than Ayala Pharmaceuticals. Ayala Pharmaceuticals is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A
Aspire Biopharma	$10K	1,157.80	-$24.48M	-$69.62	N/A

Summary

Ayala Pharmaceuticals and Aspire Biopharma tied by winning 6 of the 12 factors compared between the two stocks.

How does Aspire Biopharma compare to Grace Therapeutics?

Grace Therapeutics (NASDAQ:GRCE) and Aspire Biopharma (NASDAQ:ASBP) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Grace Therapeutics has a net margin of 0.00% compared to Aspire Biopharma's net margin of -11,362.21%. Aspire Biopharma's return on equity of 0.00% beat Grace Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-36.11%	-34.39%
Aspire Biopharma	-11,362.21%	N/A	-177.59%

Grace Therapeutics has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market. Comparatively, Aspire Biopharma has a beta of 0.11, meaning that its stock price is 89% less volatile than the broader market.

Grace Therapeutics has higher earnings, but lower revenue than Aspire Biopharma. Grace Therapeutics is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grace Therapeutics	N/A	N/A	-$7.79M	-$1.18	N/A
Aspire Biopharma	$10K	1,157.80	-$24.48M	-$69.62	N/A

In the previous week, Aspire Biopharma had 1 more articles in the media than Grace Therapeutics. MarketBeat recorded 2 mentions for Aspire Biopharma and 1 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 0.00 equaled Aspire Biopharma'saverage media sentiment score.

Company	Overall Sentiment
Grace Therapeutics	Neutral
Aspire Biopharma	Neutral

6.1% of Grace Therapeutics shares are held by institutional investors. Comparatively, 19.2% of Aspire Biopharma shares are held by institutional investors. 10.8% of Grace Therapeutics shares are held by insiders. Comparatively, 5.8% of Aspire Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Grace Therapeutics presently has a consensus target price of $6.00, indicating a potential upside of 172.73%. Given Grace Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Grace Therapeutics is more favorable than Aspire Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Grace Therapeutics beats Aspire Biopharma on 9 of the 14 factors compared between the two stocks.

Get Aspire Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ASBP vs. The Competition

Export

Metric	Aspire Biopharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$10.95M	$12.54B	$7.35B	$12.72B
Dividend Yield	N/A	2.61%	2.53%	11.02%
P/E Ratio	-0.12	778.14	270.96	24.14
Price / Sales	1,157.80	754.40	634.76	101.59
Price / Cash	N/A	98.02	78.57	53.12
Price / Book	0.99	12.02	13.14	6.25
Net Income	-$24.48M	$2.80B	$3.46B	$347.86M
7 Day Performance	4.68%	2.88%	1.52%	0.98%
1 Month Performance	13.91%	6.55%	8.82%	5.24%
1 Year Performance	-98.70%	8.09%	26.08%	17.04%

Aspire Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ASBP Aspire Biopharma	0.68 of 5 stars	$8.27 +5.9%	N/A	-98.7%	$10.95M	$10K	N/A	N/A	News Coverage Gap Down
NTRB Nutriband	0.1398 of 5 stars	$3.30 +3.4%	N/A	-24.6%	$40.11M	$2.04M	N/A	10
IXHL Incannex Healthcare	2.6952 of 5 stars	$3.28 +3.8%	$18.00 +448.8%	-83.1%	$39.25M	N/A	N/A	3	News Coverage Upcoming Earnings
RFAI RF Acquisition Corp II	1.0243 of 5 stars	$11.08 +0.0%	N/A	+381.8%	$38.95M	N/A	N/A	N/A	Short Interest Increase
ADXS Ayala Pharmaceuticals	N/A	$0.60 flat	N/A	N/A	$35.79M	$3.24M	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ASBP) was last updated on 8/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aspire Biopharma (ASBP) Competitors

ASBP vs. NTRB, IXHL, RFAI, ADXS, and GRCE

How does Aspire Biopharma compare to Nutriband?

Summary

How does Aspire Biopharma compare to Incannex Healthcare?

Summary

How does Aspire Biopharma compare to RF Acquisition Corp II?

Summary

How does Aspire Biopharma compare to Ayala Pharmaceuticals?

Summary

How does Aspire Biopharma compare to Grace Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASBP vs. The Competition

Aspire Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aspire Biopharma (ASBP) Competitors

ASBP vs. NTRB, IXHL, RFAI, ADXS, and GRCE

How does Aspire Biopharma compare to Nutriband?

Does the media favor NTRB or ASBP?

Which has more volatility & risk, NTRB or ASBP?

Do institutionals & insiders believe in NTRB or ASBP?

Is NTRB or ASBP more profitable?

Which has higher earnings and valuation, NTRB or ASBP?

Do analysts rate NTRB or ASBP?

Summary

How does Aspire Biopharma compare to Incannex Healthcare?

Which has more volatility & risk, ASBP or IXHL?

Does the media favor ASBP or IXHL?

Do analysts prefer ASBP or IXHL?

Is ASBP or IXHL more profitable?

Do institutionals and insiders have more ownership in ASBP or IXHL?

Which has preferable valuation and earnings, ASBP or IXHL?

Summary

How does Aspire Biopharma compare to RF Acquisition Corp II?

Is RFAI or ASBP more profitable?

Do analysts prefer RFAI or ASBP?

Which has better valuation & earnings, RFAI or ASBP?

Do institutionals and insiders have more ownership in RFAI or ASBP?

Does the media refer more to RFAI or ASBP?

Summary

How does Aspire Biopharma compare to Ayala Pharmaceuticals?

Is ADXS or ASBP more profitable?

Do analysts rate ADXS or ASBP?

Which has more risk and volatility, ADXS or ASBP?

Does the media refer more to ADXS or ASBP?

Do institutionals & insiders believe in ADXS or ASBP?

Which has preferable valuation & earnings, ADXS or ASBP?

Summary

How does Aspire Biopharma compare to Grace Therapeutics?

Is GRCE or ASBP more profitable?

Which has more risk and volatility, GRCE or ASBP?

Which has stronger earnings and valuation, GRCE or ASBP?

Does the media favor GRCE or ASBP?

Do institutionals and insiders have more ownership in GRCE or ASBP?

Do analysts recommend GRCE or ASBP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASBP vs. The Competition

Aspire Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools